Moderna (MRNA) Stock Forecast & Price Target

Moderna is supported by a broad mRNA platform with 25 development candidates in clinical studies as of March 2026, spanning infectious disease, oncology, cardiovascular disease, and rare genetic diseases, which expands optionality beyond the COVID franchise. Its fundamental outlook is strengthened by 3Q:26 product sales of $1.27 billion, raised 2026 revenue guidance to 15-25% growth, and an $8 billion cash balance versus $3.19 billion in long-term debt, suggesting enough financial flexibility to pursue pipeline advancement and likely regain profitability in 2028. The standout catalyst is INTerpath-001, where KEYTRUDA + intismeran improved RFS by 42% and DMFS by 38%, supporting a path to global filings and potential 2027 melanoma approval while creating a credible platform for additional oncology indications.

Moderna is viewed negatively because its core mRNA pipeline remains exposed to significant clinical and regulatory risk, with products that could fail in the clinic or never gain approval despite the platform’s validation from the covid vaccine authorized in the United States in December 2020. Even with 25 mRNA development candidates in clinical studies as of March 2026 across infectious disease, oncology, cardiovascular disease, and rare genetic diseases, the breadth of the pipeline does not eliminate the risk that multiple programs disappoint or fail to produce durable commercial returns. The outlook is further pressured by the possibility that Moderna may miss sales forecasts and spend more than budgeted, which could weaken operating leverage and limit the payoff from its commercial-stage franchise.